Invention Grant
- Patent Title: Selective FKBP51 ligands for treatment of psychiatric disorders
-
Application No.: US15703056Application Date: 2017-09-13
-
Publication No.: US10246413B2Publication Date: 2019-04-02
- Inventor: Steffen Gaali , Felix Hausch , Alexander Kirschner , Xixi Feng , Andreas Bracher , Gerd Ruehter
- Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Applicant Address: DE Munich
- Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Current Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Current Assignee Address: DE Munich
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: EP13185247 20130919; EP13196561 20131210; EP14151510 20140116
- Main IPC: C07D233/44
- IPC: C07D233/44 ; A61K31/415 ; C07D405/12 ; C07D207/16 ; C07D401/14 ; C07D401/12 ; C07D279/12 ; C07D211/60 ; C07D211/78 ; C12N9/90 ; G06F19/16 ; C07K5/078
Abstract:
The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
Public/Granted literature
- US20180072667A1 SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS Public/Granted day:2018-03-15
Information query
